A large-scale lentivirus manufacturing platform to accelerate time to clinic

Cell and Gene Therapy Insights 2023; 9(5), 503


Published: 3 June 2023
Brian Mullan

Watch the video or view the poster to learn more about:

  • LentiSure™, a proven large-scale lentivirus production platform to accelerate time to clinic of lentivirus-based cell and gene therapies 
  • Achieving high titers, transduction efficiency, dependability, and scalable production processes with improved purification methods 
  • Optimized analytical methods to allow faster development and improved patient results